SPATA31E1

Across TCGA pan-cancer cohorts, SPATA31E1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPATA31E1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPATA31E1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA31E1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LIHC, BLCA, and ACC are the cancer types where SPATA31E1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BLCA	DFS	Median	All	0.873	0.323	.013	12	view →
ACC	DFS	Median	IV	0.010	0.383	<.001	9	view →
LUAD	DFS	Median	II,III,IV	0.291	0.689	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
UCEC	DFS	Median	II,III,IV	0.853	0.431	.030	4	view →
SKCM	DFS	Median	All	0.581	0.771	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPATA31E1–LIHC (DFS)

Open the LIHC breakdown →